LUMYKRAS 120 mg film-coated tablets
Sponsors
Deciphera Pharmaceuticals Inc., Verastem Inc., Stichting Radboud University Medical Center, Institut Gustave Roussy, Fundacion GECP
Conditions
Advanced Solid TumorHealthy subjectsIIIBIIIC) KRAS p.G12C non-small cell lung cancerMetastatic Solid TumorNon Small Cell Lung CancerNon-Small Cell Lung CancerNon-small cell lung cancer
Phase 1
A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203)
Active, not recruitingCTIS2023-505107-24-00
Start: 2023-11-14Target: 48Updated: 2025-10-29
A Phase 1/2, First in Human Study of DCC-3116 as Monotherapy and in Combination With RAS/MAPK Pathway Inhibitors in Patients With Advanced or Metastatic Solid Tumors With RAS/MAPK Pathway Mutations
CompletedCTIS2022-501474-19-00
End: 2025-09-12Target: 76Updated: 2025-06-13
Phase 2
An Interventional and Translational Study investigating Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C (CODEBREAK)
Active, not recruitingCTIS2024-510837-16-00
Start: 2022-12-13Target: 40Updated: 2025-12-05
Phase II clinical trial of AMG510 (Sotorasib) in stage III unresectable NSCLC KRAS p.G12C patients_MERIT-lung
RecruitingCTIS2024-511268-10-00
Start: 2022-05-25Target: 19Updated: 2025-09-09
DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:”
“A multi-arms prospective, randomized phase II study to evaluate the best sequential
therapeutic strategis in patients with metastatic non-small cell lung cancer harboring
targetable genomic driver alterations”
Not yet recruitingCTIS2026-525268-16-00
Target: 962Updated: 2026-10-19